A ticket to ride: peptide radiopharmaceuticals.

  title={A ticket to ride: peptide radiopharmaceuticals.},
  author={Alan J. Fischman and John W Babich and H. William Strauss},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  volume={34 12},
Over the past three decades, biospecific imaging agents have evolved from large proteins (i.e., antibodies) to antibody fragments (i.e., F(ab')2 and Fab fragments) to smaller "molecular recognition units" such as Fv fragments, antigen binding domain fragments and small biologically active peptides. The smaller size of these molecules confers desirable pharmacokinetic properties, such as higher target-to-background ratios and faster blood clearance, that are favorable for imaging. Molecular… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 38 extracted citations

FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection

European Journal of Nuclear Medicine and Molecular Imaging • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…